Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products

Release Date: January 28, 2019

Glasgow, United Kingdom; 28th January 2019: Sistemic Ltd. is pleased to announce that it has received Notification of Intention to Grant by the European Patent Office for the patent application entitled “Cell Characterisation” (European Patent Application No 11760806.7).

The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.

This patent is also the first of a number of patent applications protecting Sistemic’s miRNA-based quality control assay, SistemPSCCheck™, which assesses the levels of residual pluripotent stem cells in derived cell preparations.

The grant of this patent is a significant expansion of Sistemic’s existing patent portfolio for core technologies in stem cell characterisation, potency assay development and quality control of stem cell products.

The company is pursuing patents covering the application of its technology in the development of cell therapies and is advancing its patent portfolio in most major world markets including Europe, USA, Japan and a number of other territories.

Jim Reid, CEO stated, "As a technology rich company, patents are a key part of the value development of the business. Expanding on our recent License Agreement announced in October 2018, the granting of this patent is further support to our strategy of providing the Cell and Gene Therapy industry with new products and tools to ensure consistent quality of product. This is critical to the industry to ensure that these promising lifesaving treatments can reach their full potential”.

David Mallinson, VP of Scientific Operations added, "It is of critical importance to Sistemic to be able to protect our core technologies. The granting of this patent is another significant milestone for Sistemic and the SistemPSCCheck™ assay ".

Sistemic

Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell and Gene Therapy research, development and manufacturing markets.

For more information contact: press@sistemic.co.uk